Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LeMaitre VascularLMAT -1.94%99 Intrinsic Value: DCF (Earnings Based) is $55.18 as of Aug. 20, 2026, which is 3841% above its 10-year median of 1.40. GuruFocus rates LMAT with a GF Score™ of 99/100 and a GF Value™ of $95.35 (Modestly Undervalued). Among 94 Medical Devices & Instruments companies, LeMaitre Vascular ranks worse than 72.34% on this metric.
Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's predictability rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.
The historical rank and industry rank for LeMaitre Vascular's Intrinsic Value: DCF (Earnings Based) or its related term are showing as below:
LMAT'
s Price-to-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.69 Med: 1.4 Max: 2.09
Current: 1.49
During the past 13 years, the highest Price-to-Intrinsic-Value-DCF (Earnings Based) Ratio of LeMaitre Vascular was 2.09. The lowest was 0.69. And the median was 1.40.
LMAT's Price-to-DCF (Earnings Based) is ranked worse than 72.34% of 94
companies
in the Medical Devices & Instruments industry
Industry Median: 1.225
vs LMAT: 1.49
Unlike valuation methods such as Net Current Asset Value, Tangible Book Value per Share, Graham Number, Median Ratio etc, discounted Cash Flow model evaluates the companies based on their future earnings power instead of their assets.
Be Aware
What you need to know about Discounted Earnings model:
1. The Discounted Earnings model evaluates a company based on its future earnings power
2. Growth is taken into account; therefore a faster growth company is worth more if everything else is the same.
3. Since we are projecting future growth, it is assumed that the company will grow at the same rate as it did during the past 10 years. Therefore this model works better for the companies that are relatively consistent performers.
4. The Discounted Earnings model works poorly for inconsistent performers like cyclicals.
5. Your expected return from the investment is a reasonable discount rate assumption.
6. A larger margin of safety should be required for companies with less predictable businesses.
You can screen for stocks that trade below their Intrinsic Value: DCF (FCF Based) and Intrinsic Value: DCF (Earnings Based) with the GuruFocus All-in-One Screener. Companies with a high Predictability Rank that trade at a discount to their Intrinsic Value: DCF (FCF Based) and Intrinsic Value: DCF (Earnings Based) can be found in the screen of Undervalued Predictable Companies.
LeMaitre Vascular Intrinsic Value: DCF (Earnings Based) Related Terms
LeMaitre Vascular Intrinsic Value: DCF (Earnings Based) Historical Data
* Premium members only.
The historical data trend for LeMaitre Vascular's Intrinsic Value: DCF (Earnings Based) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, LeMaitre Vascular's Price-to-DCF (Earnings Based), along with its competitors' market caps and Price-to-DCF (Earnings Based) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LeMaitre Vascular Price-to-DCF (Earnings Based) vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, LeMaitre Vascular's Price-to-DCF (Earnings Based) distribution charts can be found below:
* The bar in red indicates where LeMaitre Vascular's Price-to-DCF (Earnings Based) falls into.
This is the intrinsic value calculated from the Discounted Earnings model with default parameters. The calculation method is the same as Discounted Cash Flow model except earnings are used in the calculation instead of free cash flow. This is the default method of calculation with GuruFocus DCF calculator.
Usually a two-stage model is used in calculating the intrinsic value with discounted cash flow model. The first stage is called growth stage; the second is called the terminal stage. In the growth stage the company grows at a faster rate. Because it cannot grow at that rate forever, a lower rate is used for the terminal stage.
GuruFocus DCF calculator is a two-stage model. The default values are defined as:
1. Discount Rate: d = 11% A reasonable discount rate assumption should be at least the long term average return of the stock market, which can be estimated from risk free rate plus risk premium of stock market. GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate and rounded up to the nearest integer. It is updated daily. The current risk-free rate is 4.70%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default. Then we added a risk premium of 6% to get the estimated discount rate. Some investors use their expected rate of return, which is also reasonable. A typical discount rate can be anywhere between 6% - 20%.
2. Growth Rate in the growth stage: g1 = 14.20%
The Growth Rate in the growth stage is initially set as the default 10-Year EPS without NRI Growth Rate. In cases where the 10-year growth rate is unavailable, it defaults to using the 5-Year EPS without NRI Growth Rate. If both the 10-year and 5-year growth rates are unavailable, the system defaults to the 3-Year EPS without NRI Growth Rate.
However, it's important to note that there is a growth rate range. If the calculated growth rate exceeds 20%, it will be capped at 20%. Conversely, if the calculated growth rate falls below 5%, it will be adjusted to 5% to maintain a reasonable range.
=>
LeMaitre Vascular's average EPS without NRI Growth Rate in the past
10 years was 14.20%,
which is between 5% and 20%. => GuruFocus defaults => Growth Rate: 14.20%
3. Years of Growth Stage: y1 = 10
4. Terminal Growth Rate: g2 = 4%
5. Years of Terminal Growth: y2 = 10
6. EPS without NRI: eps without nri = $2.605. GuruFocus DCF calculator is actually a Discounted Earnings calculator, EPS without NRI is used as the default. The reason we are doing this is we found that historically stock prices are more correlated with earnings than free cash flow.
All of the default settings can be changed and the results are calculated automatically.
LeMaitre Vascular's Intrinsic Value: DCF (Earnings Based) for today is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: DCF (Earnings Based) of $55.18 mean?
LeMaitre Vascular (LMAT) has a Intrinsic Value: DCF (Earnings Based) of $55.18 as of Aug. 20, 2026. Intrinsic Value: DCF (Earnings Based) is the stock value based on a two-stage discounted earnings model. View historical data on LeMaitre Vascular and its competitors. This is 3841% above median its historical median of 1.40. Over the past decade, LeMaitre Vascular's Intrinsic Value: DCF (Earnings Based) has ranged from 0.69 to 2.09. According to the industry distribution chart, LeMaitre Vascular ranks #68 out of 94 companies in the Medical Devices & Instruments industry, placing it in the top 72.3%.
Is LeMaitre Vascular's Intrinsic Value: DCF (Earnings Based) too high?
LeMaitre Vascular's current Intrinsic Value: DCF (Earnings Based) of $55.18 is 3841% above median its 10-year median of 1.40. Over the past 10 years, this metric has ranged from a low of 0.69 to a high of 2.09. The Medical Devices & Instruments industry median Intrinsic Value: DCF (Earnings Based) is 1.23. LeMaitre Vascular's value of $55.18 is 4404.5% above this industry median. Based on the distribution chart, LeMaitre Vascular ranks #68 out of 94 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, LeMaitre Vascular has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does LeMaitre Vascular's Intrinsic Value: DCF (Earnings Based) compare to PLSE and XRAY?
According to the Medical Devices & Instruments industry distribution chart, LeMaitre Vascular ranks #68 out of 94 companies for Intrinsic Value: DCF (Earnings Based). This places LeMaitre Vascular in the lower half of its industry. The industry median Intrinsic Value: DCF (Earnings Based) is 1.23. LeMaitre Vascular's value of $55.18 is 4404.5% above this benchmark. Historically, LeMaitre Vascular's own Intrinsic Value: DCF (Earnings Based) has ranged from 0.69 to 2.09 over the past decade. While the company's 10-year median is 1.40 vs. the industry median of 1.23, LeMaitre Vascular has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: DCF (Earnings Based) for a Medical Devices & Instruments company?
The median Intrinsic Value: DCF (Earnings Based) among Medical Devices & Instruments companies is 1.23, based on 94 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: DCF (Earnings Based) significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: DCF (Earnings Based) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LeMaitre Vascular's current Intrinsic Value: DCF (Earnings Based) of $55.18 is 4404.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: DCF (Earnings Based) mean?
A high Intrinsic Value: DCF (Earnings Based) can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: DCF (Earnings Based) is the stock value based on a two-stage discounted earnings model. View historical data on LeMaitre Vascular and its competitors. For the Medical Devices & Instruments industry, the median Intrinsic Value: DCF (Earnings Based) is 1.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LeMaitre Vascular's current Intrinsic Value: DCF (Earnings Based) is $55.18, which is 3841% above median its own 10-year median of 1.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LeMaitre Vascular stock overvalued right now?
Based on GuruFocus' analysis, LeMaitre Vascular (LMAT) is currently considered Modestly Undervalued. The stock's GF Value™ is $95.35, compared to a current price of $82.34 — trading 13.6% below its estimated fair value. The current Intrinsic Value: DCF (Earnings Based) is $55.18, which is 3841% above median its 10-year median of 1.40 and 4404.5% above the Medical Devices & Instruments industry median of 1.23. LeMaitre Vascular's overall GF Score™ is 99/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: DCF (Earnings Based) calculated?
Intrinsic Value: DCF (Earnings Based) is calculated from a company's financial statements. For LeMaitre Vascular (LMAT), the current Intrinsic Value: DCF (Earnings Based) is $55.18 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LeMaitre Vascular (LMAT) Overvalued in 2026?
Based on GuruFocus' analysis, LeMaitre Vascular stock appears to be undervalued.
The current stock price of $82.34 is trading 13.6% below its estimated GF Value™ of $95.35.
GuruFocus considers LeMaitre Vascular to be Modestly Undervalued.
Key valuation signals for LMAT:
Intrinsic Value: DCF (Earnings Based): $55.18 (3841% above median its 10-year median of 1.40)
GF Value™: $95.35 vs. price of $82.34 (13.6% below fair value)
Industry Position: 4404.5% above the Medical Devices & Instruments median (#68 of 94)
No single metric tells the full story. See the LMAT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
99GF Score
Get the complete analysis for LMAT
Intrinsic Value: DCF (Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LMAT has been successfully added to your 
